1. Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing
   Han Bai et al, 2021, Cancer Management and Research CrossRef
2. ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’
   Maria Ilenia Passalacqua et al, 2022, Expert Opinion on Investigational Drugs CrossRef
3. PIK3CA and TP53 MUTATIONS and SALL4, PTEN and PIK3R1 GENE EXPRESSION LEVELS in BREAST CANCER
   Ebubekir Dirican et al, 2020, Turkish Journal of Biochemistry CrossRef
4. The prognostic value of stem cell markers in triple-negative breast cancer
   Szintia Almási et al, 2023, Pathology and Oncology Research CrossRef
5. Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
   Ya Guo et al, 2022, International Journal of Genomics CrossRef
6. Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis
   Huilan Zeng et al, 2020, BMC Cancer CrossRef
7. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer
   Yutong Fang et al, 2024, Aging CrossRef
8. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers
   Mengjing Cui et al, 2022, Frontiers in Genetics CrossRef
9. Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
   Jesse Lopes da Silva et al, 2021, Frontiers in Oncology CrossRef